Find investors
← Back to all investors
Hugh Lenon
ResearchedAngel Investors

Hugh Lenon

Chairman

Angel InvestorsSeed Round
Pitch Hugh

Get their honest, personalized take on your startup.

Sign in to pitch Hugh

At a glance

Full Name
Philip Hugh Lenon
Title
Senior Adviser (former non-executive Chairman); co-founder and Investment Committee member
Firm
Phoenix Equity Partners
Firm Type
Mid-market private equity (buyout & growth) — *not* an angel investor
Investment Stage
Established, founder-led / management-buyout and growth companies (not seed/early-stage)
Check Size
Approximately £10–80 million of equity per investment (firm strategy)
Target Company Profile
Founder-led, profitable, established mid-market businesses with proven models — the firm explicitly backs "nurturing entrepreneurs and their teams" rather than early-stage ventures
Sector Focus
Data & analytics; technology & specialist services; health & wellbeing — sectors with "long-term structural tailwinds"
Geographic Focus
United Kingdom (with portfolio-company expansion into Europe)
Location
London, UK (Phoenix Equity Partners, 123 Victoria Street, London SW1E 6DE)

Background

Hugh Lenon (formally Philip Hugh Lenon) is one of the original founders of Phoenix Equity Partners, a London-based mid-market private equity firm established in 2001 by Lenon alongside Sandy Muirhead, James Thomas, David Burns and Kevin Keck. The team spun the business out of the private equity arm of Donaldson, Lufkin & Jenrette (DLJ), where Lenon had served as a Managing Director from 1997 to 2001. By his own account Phoenix "has been an important part of my life for 33 happy years," reflecting his tenure with the firm and its predecessor operations across more than three decades.

Earlier in his career, Lenon trained and worked as an auditor and corporate financier at Deloitte from roughly 1982 to 1986 before moving into private equity investing. Over the course of more than 30 years he built a reputation across the UK private equity industry, culminating in his election as Chairman of the British Private Equity and Venture Capital Association (BVCA), the sector's trade body, for the 2010/11 term.

At Phoenix, Lenon served as Managing Partner until 2013, when leadership of the firm's day-to-day investing passed to a new generation — David Burns and Richard Daw became Managing Partners in 2014. Lenon then took the role of non-executive Chairman, which he held until 1 January 2025, when he stepped back to become a Senior Adviser to the firm while continuing to sit on Phoenix's Investment Committee. In that role he acts as a sounding board on portfolio matters, serves as chair/non-executive director for portfolio companies, and lends his network to founders and management teams.

Outside Phoenix, Lenon chairs a range of commercial and not-for-profit organisations and has a particular interest in the criminal justice space. He has also returned to formal study, pursuing a Master's degree in Near and Middle Eastern Studies at SOAS University of London (2024–2026).

Investment Thesis & Focus

  • Backs founder-led, established mid-market companies — Phoenix "partners with founder-entrepreneurs to expand their businesses" via buyout and growth strategies, explicitly favouring proven models over early-stage risk.
  • Concentrates on three sector themes with "long-term structural tailwinds": data & analytics, technology & specialist services, and health & wellbeing.
  • Typical equity cheque of £10–80 million, targeting UK (and increasingly European) mid-market opportunities; the firm manages roughly £900m and raised over £600m across its Flagship and Growth Partnership funds in 2024.
  • Emphasises culture, passion and purpose in management teams — Phoenix positions itself as an active, relationship-driven partner "rather than passive investors."
  • Note: the "angel investor / seed round" characterisation in the source stub is inaccurate — Lenon and Phoenix operate in mid-market buyout/growth PE, not seed-stage angel investing.

Notable Investments

  • Cybanetix — cybersecurity / managed detection & response services.
  • London Gynaecology — women's health / specialist clinical services.
  • Envisage Dental — dental services group (buy-and-build in specialist healthcare).
  • FutureMeds — clinical trial site network / clinical research management.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.